Search

Your search keyword '"Donswijk, Maarten L."' showing total 346 results
Start Over Author "Donswijk, Maarten L."
346 results on '"Donswijk, Maarten L."'

10. Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Author

Meijer, Dennie, van Leeuwen, Pim J., Eppinga, Wietse S.C., Vanneste, Ben G.L., Meijnen, Philip, Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Bodar, Yves J.L., Ettema, Rosemarijn H., de Bie, Katelijne C.C., Oudshoorn, Frederik H.K., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Heymans, Martijn W., Oprea-Lager, Daniela E., Schaake, Eva E., and Vis, André N.

Published
2024
Full Text
View/download PDF

13. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography

Author

Vis, André N., Meijer, Dennie, Roberts, Matthew J., Siriwardana, Amila R., Morton, Andrew, Yaxley, John W., Samaratunga, Hemamali, Emmett, Louise, van de Ven, Peter M., Heymans, Martijn W., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Boellaard, Thierry N., Schoots, Ivo G., Stricker, Phillip, Haynes, Anne-Maree, Oprea-Lager, Daniela E., Coughlin, Geoffrey D., and van Leeuwen, Pim J.

Published
2023
Full Text
View/download PDF

20. Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.

Author

Roberts, Matthew J., Papa, Nathan, Veerman, Hans, de Bie, Katelijne, Morton, Andrew, Franklin, Anthony, Raveenthiran, Sheliyan, Yaxley, William J., Donswijk, Maarten L., van der Poel, Henk G., Samaratunga, Hemamali, Wong, David, Brown, Nicholas, Parkinson, Robert, Gianduzzo, Troy, Kua, Boon, Coughlin, Geoffrey D., Oprea‐Lager, Daniela E., Emmett, Louise, and van Leeuwen, Pim J.

Subjects
PROPORTIONAL hazards models, MAGNETIC resonance imaging, RADICAL prostatectomy, OVERALL survival, COMPUTED tomography, GLEASON grading system
Abstract

Objectives: To construct and externally calibrate a predictive model for early biochemical recurrence (BCR) after radical prostatectomy (RP) incorporating clinical and modern imaging characteristics of the primary tumour. Patients and Methods: Patients who underwent RP following multiparametric magnetic resonance imaging, prostate biopsy and prostate‐specific membrane antigen‐positron emission tomography/computed tomography (PSMA‐PET/CT), from two centres in Australia and the Netherlands. The primary outcome was biochemical recurrence‐free survival (BRFS), where BCR was defined as a rising PSA level of ≥0.2 ng/mL or initiation of postoperative treatment per clinician discretion. Proportional hazards models to predict time to event were developed in the Australian sample using relevant pre‐ and post‐surgical parameters and primary tumour maximum standardised uptake value (SUVmax) on diagnostic PSMA‐PET/CT. Calibration was assessed in an external dataset from the Netherlands with the same inclusion criteria. Results: Data from 846 patients were used to develop the models. Tumour SUVmax was associated with worse predicted 3‐year BRFS for both pre‐ and post‐surgical models. SUVmax change from 4 to 16 lessened the predicted 3‐year BRFS from 66% to 42% for a patient aged 65 years with typical pre‐surgical parameters (PSA level 8 ng/mL, Prostate Imaging‐Reporting and Data System score 4/5 and biopsy Gleason score ≥4 + 5). Considering post‐surgical variables, a patient with the same age and PSA level but pathological stage pT3a, RP Gleason score ≥4 + 5 and negative margins, SUVmax change from 4 to 16 lessened the predicted 3‐year BRFS from 76% to 61%. Calibration on an external sample (n = 464) showed reasonable performance; however, a tendency to overestimate survival in patients with good prognostic factors was observed. Conclusion: Tumour SUVmax on diagnostic PSMA‐PET/CT has utility additional to commonly recognised variables for prediction of BRFS after RP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Staging Accuracy and Prognostic Value of Prostate-Specific Membrane Antigen PET/CT Strongly Depends on Lymph Node Tumor Burden.

Author

Özman, Oktay, Veerman, Hans, Contieri, Roberto, Droghetti, Matteo, Donswijk, Maarten L., Hagens, Marinus J., Van Leeuwen, Pim J., Vis, André N., and van der Poel, Henk G.

Subjects
POSITRON emission tomography computed tomography, PROSTATE-specific membrane antigen, POSITRON emission tomography, COMPUTED tomography, RADICAL prostatectomy
Abstract

Objectives: To explore the factors affecting the lymph node metastasis (LNM) detection performance of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and to evaluate its prognostic value for biochemical recurrence after radical prostatectomy (RP). Methods: Patients who had intermediate- or high-risk prostate cancer and underwent robot-assisted (RA)RP between 2017 and 2021 were included. Initial lymph node staging was carried out using PSMA PET/CT. Sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values were calculated. A cut-off value for LNM tumor deposit size that maximizes specificity was investigated and a post hoc specificity analysis was carried out. In survival analysis for biochemical progression-free survival (bPFS) after RP, Kaplan–Meier curves of molecular imaging (mi)N0 and miN1 patients were compared using the log-rank test and separate Cox regression models were developed to reveal the significance of PSMA PET/CT staging in pre- and post-surgery settings. Results: In 583 patients with a prevalence of pathology-proven LNM of 27.4%, overall sensitivity, specificity, PPV, and NPV of PSMA PET/CT per patient were 26.3% [95%CI 18.9–35.5], 93.9% [95%CI 84.9–100], 61.8% [95%CI 44.5–83.5], and 77.1% [95%CI 69.7–85.1], respectively. PSMA PET/CT showed a better sensitivity as LNM tumor deposit size increased (p = 0.003 OR 2.4 [95%CI 1.3–4.4]) and a better specificity in pT3-4 tumors (96.1%) versus pT2 (91.1%, p = 0.024 OR 2.7 [95%CI 1.1–6.3]). After adjustment according to 5.5 mm LNM tumor deposit size, which showed the best discriminative performance (AUC: 0.905 [95%CI 0.804–1.000, p < 0.001]), overall sensitivity tripled (90.2%, p < 0.001). The 1-year bPFS was 56.0% and 83.3% for miN1 and miN0 patients, respectively (p < 0.001). Whereas miN0pN1 was not, miN1pN1 disease was independently associated with decreased bPFS (HR:2.1 95%CI 1.3–3.4, p < 0.001). Conclusions: PSMA PET/CT has a lymph node tumor burden-dependent and cohort-driven diagnostic ability but consequently a strong independent prognostic value for predicting biochemical recurrence after RARP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study

Author

Meijer, Dennie, van Leeuwen, Pim J., Roberts, Matthew J., Siriwardana, Amila R., Morton, Andrew, Yaxley, John W., Samaratunga, Hemamali, Emmett, Louise, van de Ven, Peter M., van der Poel, Henk G., Donswijk, Maarten L., Boellaard, Thierry N., Schoots, Ivo G., Oprea-Lager, Daniela E., Coughlin, Geoffrey D., and Vis, André N.

Published
2021
Full Text
View/download PDF

27. Impact van de 18F-DCFPyL PET/CT-scan op het behandeladvies voor patiënten met prostaatkanker en een biochemisch recidief na curatieve therapie

Author

Meijer, Dennie, Ettema, Rosemarijn H., van Leeuwen, Pim J., Oosterholt, Pepijn M. J., Bodar, Yves J. L., van der Poel, Henk G., Hendrikse, N. Harry, Donswijk, Maarten L., Wondergem, Maurits, Vellekoop, Annelies E., van Moorselaar, R. Jeroen A., Nieuwenhuijzen, Jakko A., Oprea-Lager, Daniela E., and Vis, André N.

Published
2021
Full Text
View/download PDF

28. Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study

Author

Meijer, Dennie, van Leeuwen, Pim J., Oosterholt, Pepijn M. J., Bodar, Yves J. L., van der Poel, Henk G., Hendrikse, N. Harry, Donswijk, Maarten L., Wondergem, Maurits, Vellekoop, Annelies E., van Moorselaar, R. Jeroen A., Nieuwenhuijzen, Jakko A., Oprea-Lager, Daniela E., and Vis, André N.

Published
2021
Full Text
View/download PDF

33. Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study

Author

Krul, Myrtle F, primary, Kok, Niels F M, additional, Osmani, Harun, additional, Buisman, Florian E, additional, Groot Koerkamp, Bas, additional, Grunhagen, Dirk J, additional, Verhoef, Cornelis, additional, Mostert, Bianca, additional, Snaebjornsson, Petur, additional, Westerink, Bram, additional, Klompenhouwer, Elisabeth G, additional, Donswijk, Maarten L, additional, Ruers, Theo J M, additional, Douma, Joeri A J, additional, van Blijderveen, Nico, additional, Kingham, T Peter, additional, D’Angelica, Michael I, additional, Kemeny, Nancy E, additional, Bolhuis, Karen, additional, Buffart, Tineke E, additional, and Kuhlmann, Koert F D, additional

Published
2024
Full Text
View/download PDF

34. Strong Correlation Between SUVmaxon PSMA PET/CT and Numeric Drop-In γ-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions

Author

Berrens, Anne-Claire, primary, Sorbi, Malou A., additional, Donswijk, Maarten L., additional, de Barros, Hilda A., additional, Azargoshasb, Samaneh, additional, van Oosterom, Matthias N., additional, Rietbergen, Daphne D.D., additional, Bekers, Elise M., additional, van der Poel, Henk G., additional, van Leeuwen, Fijs W.B., additional, and van Leeuwen, Pim J., additional

Published
2024
Full Text
View/download PDF

35. 99mTcPSMA‐radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE‐II trial

Author

Zuur, Lotte G., primary, de Barros, Hilda A., additional, van Oosterom, Matthias N., additional, Berrens, Anne‐Claire, additional, Donswijk, Maarten L., additional, Hendrikx, Jeroen J.M.A., additional, Bekers, Elise M., additional, Vis, André N., additional, Wit, Esther M., additional, van Leeuwen, Fijs B., additional, van der Poel, Henk G., additional, and van Leeuwen, Pim J., additional

Published
2024
Full Text
View/download PDF

37. The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer

Author

Zorgeenheid Urologie Medisch, Researchgr. Nucleaire Geneeskunde, Cancer, Donswijk, Maarten L., Ettema, Rosemarijn H., Meijer, Dennie, Wondergem, Maurits, Cheung, Zing, Bekers, Elise M., van Leeuwen, Pim J., van den Bergh, Roderick C.N., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Zorgeenheid Urologie Medisch, Researchgr. Nucleaire Geneeskunde, Cancer, Donswijk, Maarten L., Ettema, Rosemarijn H., Meijer, Dennie, Wondergem, Maurits, Cheung, Zing, Bekers, Elise M., van Leeuwen, Pim J., van den Bergh, Roderick C.N., van der Poel, Henk G., Vis, André N., and Oprea-Lager, Daniela E.

Published
2024

38. Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Author

MS Radiotherapie, Cancer, Meijer, Dennie, van Leeuwen, Pim J., Eppinga, Wietse S.C., Vanneste, Ben G.L., Meijnen, Philip, Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Bodar, Yves J.L., Ettema, Rosemarijn H., de Bie, Katelijne C.C., Oudshoorn, Frederik H.K., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Heymans, Martijn W., Oprea-Lager, Daniela E., Schaake, Eva E., Vis, André N., MS Radiotherapie, Cancer, Meijer, Dennie, van Leeuwen, Pim J., Eppinga, Wietse S.C., Vanneste, Ben G.L., Meijnen, Philip, Daniels, Laurien A., van den Bergh, Roderick C.N., Lont, Anne P., Bodar, Yves J.L., Ettema, Rosemarijn H., de Bie, Katelijne C.C., Oudshoorn, Frederik H.K., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Heymans, Martijn W., Oprea-Lager, Daniela E., Schaake, Eva E., and Vis, André N.

Published
2024

39. The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer

Author

Donswijk, Maarten L, Ettema, Rosemarijn H, Meijer, Dennie, Wondergem, Maurits, Cheung, Zing, Bekers, Elise M, van Leeuwen, Pim J, van den Bergh, Roderick C N, van der Poel, Henk G, Vis, André N, Oprea-Lager, Daniela E, Donswijk, Maarten L, Ettema, Rosemarijn H, Meijer, Dennie, Wondergem, Maurits, Cheung, Zing, Bekers, Elise M, van Leeuwen, Pim J, van den Bergh, Roderick C N, van der Poel, Henk G, Vis, André N, and Oprea-Lager, Daniela E

Abstract

PURPOSE: Prostate-specific membrane antigen (PSMA) positron emission tomography/ computed tomography (PET/CT) is recognized as the most accurate imaging modality for detection of metastatic high-risk prostate cancer (PCa). Its role in the local staging of disease is yet unclear. We assessed the intra- and interobserver variability, as well as the diagnostic accuracy of the PSMA PET/CT based molecular imaging local tumour stage (miT-stage) for the local tumour stage assessment in a large, multicentre cohort of patients with intermediate and high-risk primary PCa, with the radical prostatectomy specimen (pT-stage) serving as the reference standard.METHODS: A total of 600 patients who underwent staging PSMA PET/CT before robot-assisted radical prostatectomy was studied. In 579 PSMA positive primary prostate tumours a comparison was made between miT-stage as assessed by four nuclear physicians and the pT-stage according to ISUP protocol. Sensitivity, specificity and diagnostic accuracy were determined. In a representative subset of 100 patients, the intra-and interobserver variability were assessed using Kappa-estimates.RESULTS: The sensitivity and specificity of the PSMA PET/CT based miT-stage were 58% and 59% for pT3a-stage, 30% and 97% for ≥ pT3b-stage, and 68% and 61% for overall ≥ pT3-stage, respectively. No statistically significant differences in diagnostic accuracy were found between tracers. We found a substantial intra-observer agreement for PSMA PET/CT assessment of ≥ T3-stage (k 0.70) and ≥ T3b-stage (k 0.75), whereas the interobserver agreement for the assessment of ≥ T3-stage (k 0.47) and ≥ T3b-stage (k 0.41) were moderate.CONCLUSION: In a large, multicentre study evaluating 600 patients with newly diagnosed intermediate and high-risk PCa, we showed that PSMA PET/CT may have a value in local tumour staging when pathological tumour stage in the radical prostatectomy specimen was

Published
2024

42. 99mTcPSMA‐radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE‐II trial.

Author

Zuur, Lotte G., de Barros, Hilda A., van Oosterom, Matthias N., Berrens, Anne‐Claire, Donswijk, Maarten L., Hendrikx, Jeroen J.M.A., Bekers, Elise M., Vis, André N., Wit, Esther M., van Leeuwen, Fijs B., van der Poel, Henk G., and van Leeuwen, Pim J.

Subjects
PROSTATE-specific membrane antigen, PROSTATE surgery, ANDROGEN deprivation therapy, PROSTATE cancer, POSITRON emission tomography, RADIOTHERAPY, LOW dose rate brachytherapy
Abstract

Objective: To investigate whether combination treatment of prostate‐specific membrane antigen (PSMA)‐based radioguided surgery (RGS) with short‐term androgen deprivation therapy (ADT) improves oncological outcomes in men with oligorecurrent prostate cancer (PCa) as compared to treatment with short‐term ADT only. Methods: The TRACE‐II study is an investigator‐initiated, prospective, randomised controlled clinical trial. Patients (aged >18 years) with hormone‐sensitive recurrent PCa after radical prostatectomy or radiotherapy (brachytherapy or external beam radiotherapy), with involvement of ≤2 lymph nodes or local oligorecurrent disease within the pelvis as determined by PSMA positron emission tomography (PET)/computed tomography (CT) are randomly assigned in a 1:1 ratio between 6‐month ADT (Arm A) or 6‐month ADT plus RGS (Arm B). The primary objective is to determine clinical progression‐free survival (CPFS) at 24 months. After PSMA‐RGS, CPFS is defined as the time between the start of treatment and the appearance of a re‐recurrence (any N1 or M1) as suggested by PSMA‐PET/CT or symptoms related to progressive PCa, or death from any cause. The secondary objectives include metastasis‐free survival at 2, 5 and 10 years, biochemical progression‐free survival at 2 years, and patient‐reported quality of life at 2, 5 and 10 years. A total of 60 patients, 30 per arm, will be included. The trial is powered (80%) to detect at least a 30% absolute difference in CPFS between the two study arms in the period 2 years after randomisation. We expect to enrol the required participants in 3 years. The study has an expected duration of 5 years in total. Conclusions: Combining RGS with short‐term ADT might be oncologically beneficial for patients with oligorecurrent PCa. In this first randomised controlled trial, we are investigating the potential oncological benefits of this combined treatment, while also focusing on maintaining quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy

Author

Geboers, Bart, primary, Meijer, Dennie, additional, Counter, William, additional, Blazevski, Alexandar, additional, Thompson, James, additional, Doan, Paul, additional, Gondoputro, William, additional, Katelaris, Athos, additional, Haynes, Anne‐Maree, additional, Delprado, Warick, additional, O'Neill, Gordon, additional, Yuen, Carlo, additional, Vis, Andre N., additional, van Leeuwen, Pim J., additional, Ho, Bao, additional, Liu, Victor, additional, Lee, Jonathan, additional, Donswijk, Maarten L., additional, Oprea‐Lager, Daniela, additional, Scheltema, Matthijs J., additional, Emmett, Louise, additional, and Stricker, Phillip D., additional

Published
2023
Full Text
View/download PDF

46. Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands

Author

Buisman, Florian E., Grünhagen, Dirk J., Homs, Marjolein Y. V., Grootscholten, Cecile, Filipe, Wills F., Kemeny, Nancy E., Cercek, Andrea, D’Angelica, Micheal I., Donswijk, Maarten L., van Doorn, Leni, Emmering, Jasper, Jarnagin, William R., Kingham, T. Peter, Klompenhouwer, Elisabeth G., Kok, Niels F. M., Kuiper, Maria C., Moelker, Adriaan, Prevoo, Warner, Versleijen, Michelle W. J., Verhoef, Cornelis, Kuhlmann, Koert F. D., and Groot Koerkamp, Bas

Published
2019
Full Text
View/download PDF

48. Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer

Author

Bodar, Yves J.L., primary, Boevé, Liselotte M.S., additional, van Leeuwen, Pim J., additional, Baars, Phillippe C., additional, Nieuwenhuijzen, Jakko A., additional, van Haarst, Ernst P., additional, Oddens, Jorg R., additional, Donswijk, Maarten L., additional, van Riel, Luigi A. M. J. G., additional, Scheltema, Matthijs J., additional, Meijer, Dennie, additional, Hendrikse, N. Harry, additional, Oprea‐Lager, Daniela E., additional, and Vis, André N., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results